Kura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update
– Update from ongoing Phase 2 trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) to be presented at
– Startup activities initiated for upcoming registration-directed trial of tipifarnib in HRAS mutant HNSCC –
– Biomarker-enriched Phase 2 trial of tipifarnib in peripheral T-cell lymphoma (PTCL) actively enrolling, data expected by year end –
– Company believes existing capital resources sufficient to fund current operations through 2021 –
– Management to host webcast and conference call today at
“I am very pleased with the continued progress we made over the past quarter, with a particular focus on operational execution,” said
- Updated data from RUN-HN at
ESMO– An abstract relating to Kura’s ongoing Phase 2 trial of tipifarnib in HRAS mutant HNSCC has been accepted for oral presentation at the upcoming European Society for Medical Oncology( ESMO) 2018 Congressin Munichin October. The update will also include patients from an exploratory cohort in other HRAS mutant squamous cell carcinomas. Approximately 25 clinical sites are now open for enrollment worldwide and RUN-HN is currently enrolling at a rate of approximately two patients per month.
- Screening collaboration to support enrollment – The company has signed an agreement with OncoDNA, an oncology-focused healthcare technology company based in
Belgium, to support patient enrollment for Kura’s ongoing Phase 2 trial of tipifarnib in patients with HRAS mutant HNSCC. OncoDNA provides physicians internationally with next-generation sequencing for HNSCC oncogenic mutations, including HRAS, for patients who may be eligible to enroll in RUN-HN.
- Registration-directed trial anticipated to initiate by year end – Kura has initiated startup activities for its upcoming registration-directed trial of tipifarnib in at least 59 recurrent or metastatic patients with HRAS mutant HNSCC. The company anticipates that the trial will be conducted at approximately 100 clinical sites worldwide and will take approximately two years to enroll. Based on feedback from the
U.S. Food and Drug Administration, Kura believes that the single-arm trial, if positive, could support an application for accelerated approval.
- HRAS mutant lung squamous cell carcinoma (LSCC) – An investigator-sponsored trial of tipifarnib in HRAS mutant LSCC has been initiated and is now open for enrollment. The proof-of-concept trial is being conducted in collaboration with the
Spanish Lung Cancer Group, a cooperative group consisting of more than 150 public and private oncology centers in Spain.
- Biomarker-enriched data in hematologic malignances – Kura is prospectively investigating the CXCL12 pathway and bone marrow homing as potential biomarkers of activity for tipifarnib in its three ongoing Phase 2 trials in hematologic malignancies. The PTCL trial was the first of the three to begin and is actively enrolling into two cohorts: 1) Patients with angioimmunoblastic T-cell lymphoma (AITL) and 2) patients with PTCL who have the absence of a single nucleotide variation in the 3’ untranslated region of the CXCL12 gene. The company expects to have biomarker-enriched data from PTCL and potentially other indications by the end of 2018.
- Strengthened management team – Kura expanded its leadership team with the additions of
Marc Grasso, M.D., and John Farnam. Dr. Grasso will join the company as Chief Financial Officer and Chief Business Officer on August 21, 2018, after 20 years in healthcare investment banking. Mr. Farnam joined Kura in the newly created position of Chief Operating Officer on July 1, 2018, from Celgene Receptos. The company has also added industry veterans Bridget Martell, M.D., and Blake Tomkinson, Ph.D., as Vice Presidents of Clinical Development.
- Public offering of common stock – On
July 2, 2018, Kura completed a public offering in which the company sold an aggregate of 4,600,000 shares of common stock at a price of $16.75per share. Net proceeds from the public offering, after deducting underwriting discounts, commissions and offering expenses, were approximately $74.5 million.
- Update from ongoing Phase 2 trial of tipifarnib in HRAS mutant HNSCC at
ESMOin October 2018
- Initiation of registration-directed trial of tipifarnib in HRAS mutant HNSCC by the end of 2018
- Dosing of first patient in investigator-sponsored study of tipifarnib in HRAS mutant LSCC
- Biomarker-enriched data from Phase 2 trial of tipifarnib in PTCL by the end of 2018
- Submission of an investigational new drug application for KO-539, a potent and selective menin-MLL inhibitor, in late 2018 or early 2019
- Research and development expenses for the second quarter of 2018 were
$11.5 million, compared to $5.7 millionfor the second quarter of 2017.
- General and administrative expenses for the second quarter of 2018 were
$3.8 million, compared to $2.3 millionfor the second quarter of 2017.
- Net loss for the second quarter of 2018 was
$14.7 million, or $0.45per share, compared to $7.8 million, or $0.40per share, for the second quarter of 2017.
- Cash, cash equivalents and short-term investments totaled
$125.9 millionas of June 30, 2018, compared with $93.1 millionas of December 31, 2017.
- As adjusted for the
$74.5 millionin net proceeds resulting from the company’s public offering of common stock that closed on July 2, 2018, Kura had, on a pro forma basis, $200.4 millionin cash, cash equivalents and short-term investments at June 30, 2018.
- Management expects that current cash, cash equivalents and short-term investments will be sufficient to fund its current operations through 2021.
Conference Call and Webcast
Kura’s management will host a webcast and conference call today at
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of Kura Oncology’s product candidates, tipifarnib, KO-947 and KO-539, progress and expected timing of Kura Oncology’s drug development programs and clinical trials, including the timing of initiation of the AIM-HN trial, and submission of regulatory filings, the presentation of data from clinical trials, plans regarding regulatory filings and future clinical trials, the regulatory approval path for tipifarnib, the strength of Kura Oncology’s balance sheet and the adequacy of cash on hand. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that
|KURA ONCOLOGY, INC.|
|Statements of Operations Data|
|(in thousands, except per share data)|
|Three Months Ended||Six Months Ended|
|June 30,||June 30,|
|Research and development||$||11,476||$||5,652||$||23,042||$||11,165|
|General and administrative||3,800||2,278||7,225||4,418|
|Total operating expenses||15,276||7,930||30,267||15,583|
|Other income, net||537||110||924||230|
|Net loss per share, basic and diluted||$||(0.45||)||$||(0.40||)||$||(0.91||)||$||(0.78||)|
|Weighted average number of
shares used in computing net loss
per share, basic and diluted
|KURA ONCOLOGY, INC.|
|Balance Sheet Data|
|June 30,||December 31,|
|Cash, cash equivalents and short-term investments||$||125,885||$||93,145|
Vice President, Investor Relations &
Westwicke Partners, LLC
Source: Kura Oncology, Inc.